Abstract:The X-linked deubiquitinase USP9X has been implicated in multiple pathological disorders including malignancies and X-linked intellectual disability. However, its biological function and substrate repertoire remain to be investigated. In this study, we utilized the tandem mass tag labeling assay to identify USP9X-regulated proteins and revealed that the expression of multiple genes is altered in USP9X-deficient cells. Interestingly, we showed that USP9X promotes stabilization of centrosome proteins PCM1 and CEP55 through its catalytic activity. Remarkably, we demonstrated that USP9X is physically associated and spatially co-localized with PCM1 and CEP55 in the centrosome, and we revealed that either PCM1 or CEP55 loss resulted in impairment of USP9X centrosome localization. Moreover, we showed that USP9X is required for centrosome duplication, and this effect is dependent on its catalytic activity and its N-terminal module, which is responsible for physical association of USP9X with PCM1 and CEP55. Collectively, our experiments identified USP9X as an integral component of the centrosome where it functions to stabilize PCM1 and CEP55 and promote centrosome biogenesis. The X-linked deubiquitinase USP9X has been implicated in multiple pathological disorders including malignancies and X-linked intellectual disability. However, its biological function and substrate repertoire remain to be investigated. In this study, we utilized the tandem mass tag labeling assay to identify USP9X-regulated proteins and revealed that the expression of multiple genes is altered in USP9X-deficient cells. Interestingly, we showed that USP9X promotes stabilization of centrosome proteins PCM1 and CEP55 through its catalytic activity. Remarkably, we demonstrated that USP9X is physically associated and spatially co-localized with PCM1 and CEP55 in the centrosome, and we revealed that either PCM1 or CEP55 loss resulted in impairment of USP9X centrosome localization. Moreover, we showed that USP9X is required for centrosome duplication, and this effect is dependent on its catalytic activity and its N-terminal module, which is responsible for physical association of USP9X with PCM1 and CEP55. Collectively, our experiments identified USP9X as an integral component of the centrosome where it functions to stabilize PCM1 and CEP55 and promote centrosome biogenesis.

USP9X Controls Translation Efficiency Via Deubiquitination of Eukaryotic Translation Initiation Factor 4A1

O-GlcNAcylation of Core Components of the Translation Initiation Machinery Regulates Protein Synthesis.

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing

Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment

Eukaryotic translation initiation factors and cancer.

SUMO-2 Promotes Mrna Translation by Enhancing Interaction Between Eif4e and Eif4g.

The X-linked Deubiquitinase USP9X is an Integral Component of Centrosome

mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3 -mediated non-degradative ubiquitination of eIF4A1

Initiation of Quality Control during Poly(A) Translation Requires Site-Specific Ribosome Ubiquitination

Eukaryotic translation initiation factor eIF4G2 opens novel paths for protein synthesis in development, apoptosis and cell differentiation.

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway

Suppression of Ribosomal Pausing by Eif5a is Necessary to Maintain the Fidelity of Start Codon Selection.

Deubiquitinase Ubiquitin‐specific Protease 9X Regulates the Stability and Function of E3 Ubiquitin Ligase Ring Finger Protein 115 in Breast Cancer Cells

Deubiquitinase USP9X Stabilizes RNA M6a Demethylase ALKBH5 and Promotes Acute Myeloid Leukemia Cell Survival.

Inhibition of Mul1-mediated ubiquitination promotes mitochondria-associated translation

Deubiquitylase USP9X Suppresses Tumorigenesis by Stabilizing Large Tumor Suppressor Kinase 2 (LATS2) in the Hippo Pathway.

USP39-Mediated Non-Proteolytic Control of ETS2 Suppresses Nuclear Localization and Activity.

mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3 IBTK -mediated ubiquitination of eIF4A1 in cancer cells

Relaxed Initiation Pausing of Ribosomes Drives Oncogenic Translation

USP10 as a Potential Therapeutic Target in Human Cancers